• JNJ-68284528) anti-BCMA CAR-T cell therapy in US patients with relapsed multiple myeloma (RRMM) refractory to both IMiD and proteasome inhibitor (PI) or with at least three prior lines of therapy and previously exposed to anti-CD38 monoclonal antibody (MoAb). (myeloma.org)
  • Dr. Luciano Costa (University of Alabama at Birmingham, Birmingham, AL, USA) explains that this study used a contemporary U.S.-based dataset of patients with multiple myeloma refractory to anti-CD38 MoAb (MAMMOTH) to identify patients who would meet eligibility for CARTITUDE-1 and who received conventional therapy. (myeloma.org)
  • Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma. (onclive.com)
  • Historically, in multiple myeloma, to receive accelerated approval for a new drug for patients with an unmet need (ie, those who had exhausted all available therapies), you needed a 20% to 30% response rate for 3 to 4 months. (onclive.com)
  • artemisinin-based combination therapies, long-lasting insecticide-treated bednets, and rapid diagnostic tests, and progress in the development of new drugs and vaccines is encouraging. (who.int)
  • A phase II study showed that patients with resected local-regionally advanced head and neck squamous cell carcinoma (HNSCC) had improved survival when pembrolizumab was added to adjuvant RT (NCT02641093). (nature.com)
  • Herein, we designed clinical trial of co-administrating imatinib mesylate and pembrolizumab (anti-PD-1 antibody) to evaluate its safety and efficacy.Methods and analysis:This is an open-label, single-arm, phase I/II clinical trial involving Japanese patients with metastatic KIT-mutant melanoma that are refractory to standard therapy including anti-PD-1 therapy. (elsevierpure.com)
  • Phase I study is a dose-escalation study comprising two dose levels of imatinib mesylate (200 and 400 mg/day, respectively) with fixed dose of pembrolizumab (200 mg every 3 weeks) to evaluate safety and tolerability and determine recommended phase II dose. (elsevierpure.com)
  • The primary endpoint of the phase II study is the objective response rate after 4 cycles (3 weeks/cycle) of pembrolizumab and imatinib mesylate at the dose determined in phase I, based on RECIST version 1.1. (elsevierpure.com)
  • Patients who are eligible will receive a combination drug therapy with pembrolizumab, a type of immune checkpoint inhibitor used to treat different cancers. (cancer.gov)
  • TOKYO―FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has begun implementation of a phase 2a study in the U.S. to evaluate safety, tolerability, and preliminary efficacy of FF-10832, a liposomal drug candidate, in combination therapy with Merck & Co., Inc., Rahway, N.J., U.S.A.'s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for patients with advanced solid tumors. (fujifilm.com)
  • The initiation of the dose-escalation stage of STELLAR-002, our second phase 1b trial of XL092, is an important step toward evaluating the potential of this next-generation tyrosine kinase inhibitor in combination with three additional immuno-oncology therapies for patients with advanced genitourinary tumors," said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. (dptribune.com)
  • WHIPPANY, N.J.- The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor (ARi) NUBEQA ® (darolutamide) in metastatic hormone-sensitive prostate cancer (mHSPC) has met its primary endpoint. (blstimes.com)
  • Methods This non-randomized, multicohort, phase II study evaluated the efficacy and safety of the anti-PD-1 antibody nivolumab 240 mg administered every 2 weeks in combination with the CDK4/6 inhibitor abemaciclib 150 mg twice daily and either fulvestrant (FUL) or letrozole (LET) as a first-line or second-line treatment for HR-positive HER2-negative metastatic breast cancer. (bmj.com)
  • The improvement in OS with the addition of darolutamide to ADT plus docetaxel was despite 76% of patients on the placebo arm receiving subsequent life-prolonging therapy with most of them receiving an AR pathway inhibitor. (urotoday.com)
  • The primary focus of the trial is to establish the safety and tolerability of FF-10832 in combination with KEYTRUDA in patients with advanced solid tumors, and evaluate its preliminary efficacy in non-small cell lung cancer (NSCLC)* 2 and urothelial cancer (UC)* 3 patients who have progressed after standard therapy, including immune checkpoint inhibitor therapy. (fujifilm.com)
  • KEYTRUDA is an anti-PD-1 immune checkpoint inhibitor therapy. (fujifilm.com)
  • Kite's lead product candidate, axicabtagene ciloleucel, previously known as KTE-C19, is an investigational therapy in which a patient's T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias, and redirect the T cells to kill cancer cells. (gilead.com)
  • Now we have game-changing T-cell-redirecting therapies, such as CAR [chimeric antigen receptor] T-cell therapies and bispecific antibodies," he explained. (onclive.com)
  • The phase I clinical trial enrolled eight adults with HIV who were on stable antiretroviral therapy for at least three months. (sciencedaily.com)
  • Second-line combination antiretroviral therapy in resource-l. (lww.com)
  • Combination antiretroviral therapy (ART) has dramatically altered the prognosis of individuals infected with HIV. (lww.com)
  • The year 2006 marked 25 years since the first description of AIDS and 10 years since the advent of the potent, combination antiretroviral therapy (ART) that has had such a dramatic success in reducing AIDS and prolonging the duration and quality of life of those living with HIV infection [1-4] . (lww.com)
  • 2 Prostate cancer that has spread beyond the prostate and does not respond to androgen-suppression therapies - a common treatment for prostate cancer - is known as metastatic CRPC. (dptribune.com)
  • Neoadjuvant androgen deprivation therapy (NADT) is systemic therapy administered after the diagnosis of prostate cancer but before locoregional therapy such as radical prostatectomy (RP) or radiation. (medscape.com)
  • However, a meta-analysis of the sequencing of androgen deprivation therapy with radiation therapy in localized prostate cancer concluded that adjuvant androgen deprivation therapy results in superior outcomes, compared with neoadjuvant or concurrent androgen deprivation therapy. (medscape.com)
  • As with any therapy, the ultimate benefit of NADT in prostate cancer will be determined only through properly designed trials with long-term follow-up. (medscape.com)
  • Participants with de novo metastatic NE prostate cancer will not be required to have been previously treated with androgen deprivation therapy (ADT). (aiom.it)
  • ARASENS is a randomized phase 3 trial of darolutamide versus placebo in combination with docetaxel and androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). (urotoday.com)
  • Ponatinib combined with chemotherapy has shown promise in achieving a second chronic phase or cytogenetic response. (thedoctorschannel.com)
  • This is a very different approach from that taken by pioneer chemotherapists in Africa, where it was felt that the host response provided an important part of therapy, and too much chemotherapy could, by abrogating immunological defences against the tumor, lead to a negative result. (hindawi.com)
  • Nonetheless, today, most patients with BL can be cured with intensive conventional chemotherapy by accepting the fact that some will be over-treated, but directing research towards trying to identify such patients and minimizing therapy to the extent possible. (hindawi.com)
  • The aim of this study (JGOG1063) was to determine the recommended dose (RD) for combination chemotherapy with irinotecan hydrochloride (CPT-11) and nedaplatin (NDP) for advanced cervical squamous cell carcinoma. (nih.gov)
  • Clinically relevant improvements in survival have been attained by administering targeted therapy to the appropriate patient population: for example, the addition of trastuzumab to standard first-line chemotherapy in patients with human epidermal growth factor receptor-positive (HER2+) metastatic breast cancer 3 . (ersjournals.com)
  • 5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. (bvsalud.org)
  • The dose-escalation stage will determine the recommended dose in patients with advanced solid tumors for each of the XL092 combination therapy regimens. (dptribune.com)
  • The safety and toxicity profile of these combination regimens needs rigorous clinical evaluation. (elsevierpure.com)
  • Combination therapy has gained momentum in oncology in recent years, with various studies demonstrating higher response rates with combinations of drugs compared to monotherapies, and the FDA recently approving therapeutic combination regimens that demonstrated superior safety and efficacy to monotherapies. (wikipedia.org)
  • 1-8 To limit the treatment burden associated with frequent anti-VEGF injections, combination regimens with macular laser photocoagulation and anti-VEGF drugs have been investigated in multiple studies to determine if they might result in fewer required interventions. (bmj.com)
  • Extrapulmonary tuberculosis should be managed according to the principles and with the drug regimens outlined for pulmonary tuberculosis, except for children who have miliary tuberculosis, bone/joint tuberculosis, or tuberculous meningitis who should receive a minimum of 12 mo of therapy. (cdc.gov)
  • The 15-year progression-free survival was 36% with adjuvant therapy versus 29% with neoadjuvant therapy ( P = 0.01). (medscape.com)
  • Adjuvant therapy was also superior with respect to biochemical failure, distant metastasis, and metastasis-free survival. (medscape.com)
  • The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial. (outsourcing-pharma.com)
  • Roche is aiming to develop the drug in earlier stages of the disease as an adjuvant therapy following surgical removal of the tumor. (outsourcing-pharma.com)
  • however, adjuvant therapy may be considered in patients with high-risk disease. (medscape.com)
  • Imeglimin is an oral antidiabetic that has demonstrated efficacy and safety in two Phase IIa trials. (genengnews.com)
  • The ARASENS trial investigating NUBEQA is the only Phase III randomized, multi-center, double-blind trial, which was prospectively designed to evaluate the efficacy and safety of a combination of an ARi with docetaxel and ADT compared to docetaxel and ADT in patients with mHSPC. (blstimes.com)
  • Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of STELLAR-002, a phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors. (dptribune.com)
  • XL092 is currently being developed for the treatment of advanced solid tumors, including genitourinary cancers, as a monotherapy and in combination with immune checkpoint inhibitors. (dptribune.com)
  • Recent precision medicine approaches have focused on targeting multiple biomarkers found in individual tumors by using combinations of drugs. (wikipedia.org)
  • The primary objective of this study was to evaluate the toxicity of combining bavituximab, an antibody that targets exposed phosphatidylserine, with capecitabine and radiation therapy. (elsevierpure.com)
  • Materials and Methods: Patients with stage II or III rectal adenocarcinoma were enrolled on a phase I study combining radiation therapy, capecitabine, and bavituximab. (elsevierpure.com)
  • Conclusions: Bavituximab is safe in combination with capecitabine and radiation therapy at the doses selected for the study. (elsevierpure.com)
  • In a recent study about solid cancers, Martin Nowak, Bert Vogelstein, and colleagues showed that in most clinical cases, combination therapies are needed to avoid the evolution of resistance to targeted drugs. (wikipedia.org)
  • Treatment with luteinizing hormone-releasing hormone agonists or antagonists for all cohorts must have been initiated ≥4 weeks prior to first dose of study therapy and must be continued throughout the study. (aiom.it)
  • Must be abstinent from heterosexual intercourse, refrain from donating sperm, or agree to use contraception (unless confirmed to be azoospermic) during the intervention period starting with the first dose of study therapy. (aiom.it)
  • This phase 2 study is examining the best treatments for TFE/Translocation type Renal Cell Carcinoma (tRCC). (columbia.edu)
  • ASCO 2020: [VIRTUAL] Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC). (larvol.com)
  • Totally, a target size of 22 patients will be expected.Discussion:If this study shows efficacy and acceptable safety profile, it will contribute to the development of novel treatment option for patients with KIT-mutant melanoma that are refractory to standard therapy.Trial registration:NCT04546074. (elsevierpure.com)
  • Updated clinical data from the Phase 1/2 study sponsored by GSK plc (LSE/NYSE: GSK) evaluating nirogacestat in combination with low-dose belamaf (belantamab mafodotin-blmf), GSK's antibody-drug conjugate targeting BCMA, in patients with RRMM will be presented in a poster presentation. (advfn.com)
  • This ongoing Phase 1/2 trial, which is sub-study 3 of GSK's DREAMM-5 platform trial (NCT04126200), aims to determine if low-dose belamaf in combination with nirogacestat results in similar efficacy with an improved ocular toxicity profile compared to belamaf alone at a higher dose. (advfn.com)
  • Methods In this pilot study we retrospectively reviewed charts and imaging of 23 eyes treated with the standardised combination regimen. (bmj.com)
  • An exploratory endpoint of the clinical phase 2a study is to determine whether encapsulating gemcitabine in liposomes enhances pharmacological efficacy. (fujifilm.com)
  • Subject to the outcome of clinical studies of specific liposome-drug combinations, including the clinical phase 2a study, liposomes are believed to be capable of delivering active ingredients to tumor sites. (fujifilm.com)
  • The drug's label also includes clinical data from the phase IV ASCENT study, which shows aclidinium therapy is effective at reducing COPD exacerbations. (pharmacytimes.com)
  • Basel, September 29, 2021 - As the threat of resistance to current malaria treatment grows, Novartis and MMV have reported positive results of a new non-artemisinin combination in a Phase 2b study. (novartis.com)
  • The study tested ganaplacide, a novel agent with an entirely new mechanism of action, in combination with a new formulation of lumefantrine that is optimised for once daily dosing. (novartis.com)
  • This Phase 2b study was an open label randomized controlled study conducted in two parts and which enrolled more than 500 patients with acute uncomplicated malaria due to Plasmodium falciparum infection. (novartis.com)
  • The ganaplacide/lumefantrine solid dispersion formulation combination met the primary objective in Part B of the study in children with acute uncomplicated malaria. (novartis.com)
  • The study found that in patients with RRMM beyond therapy with IMiD, PI, and anti-CD38 MoAb, treatment with cilta-cel is associated with higher response rates and superior progression-free survival and overall survival when compared to conventional treatment. (myeloma.org)
  • In a Phase Ib study, Biogen's BIIB080 successfully reduced tau pathology in patients with early-stage AD, measured by PET scan, across all six brain regions analyzed. (biospace.com)
  • Participants received different dosing frequency in the Phase Ib study with cohorts at once per month and once per three months. (biospace.com)
  • Eisai is also developing a tau antibody, which is currently in a Phase II/III study for dominantly inherited AD, with Leqembi as the base therapy. (biospace.com)
  • The PGHHS recommended in place of drug treatment for comprises 2 major components: Phase I patients who fall into an intermediate range is a cross-sectional prevalence study of for coronary heart disease risk [ 6 ]. (who.int)
  • The phase 2 study was conducted in 108 patients who were experiencing relapse after one or two previous lines of therapy, including the pemetrexed /platinum doublet. (medscape.com)
  • This phase 2 study is the largest so far in this setting, and I expect that it will pave the way for more practice-changing research in malignant pleural mesothelioma," said Hongbin Chen, MD, PhD, a medical oncologist at the Roswell Park Cancer Institute in Buffalo, New York, who was not involved in the research. (medscape.com)
  • Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. (cdc.gov)
  • Results: In general, bavituximab was safe and well tolerated in combination with radiation therapy and capecitabine in the treatment of rectal adenocarcinoma. (elsevierpure.com)
  • Over half of cancer patients undergo radiation therapy (RT). (nature.com)
  • However, the NCCN notes that androgen deprivation therapy before, during, and/or after radiation prolongs survival in selected patients who are receiving radiation therapy only. (medscape.com)
  • 5 years, the NCCN guidelines support the use of external beam radiation therapy (EBRT) and NADT. (medscape.com)
  • Radiation therapy to the breast or chest. (cancer.gov)
  • Treatment using adeno-associated viral vector is poised to move into larger, later-phase trials. (sciencedaily.com)
  • One tumor demonstrated a complete pathologic response to the combination treatment. (elsevierpure.com)
  • Combination therapy may seem costlier than monotherapy in the short term, but when it is used appropriately, it causes significant savings: lower treatment failure rate, lower case-fatality ratios, fewer side-effects than monotherapy, slower development of resistance, and thus less money needed for the development of new drugs. (wikipedia.org)
  • Otsuka Pharmaceutical Co., Ltd. today announced that the European Commission has granted a marketing authorization for Deltyba (delamanid) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. (news-medical.net)
  • Gene therapy is under development for the treatment of Parkinson's disease and multiple system atrophy. (globaldata.com)
  • Guided self-help cognitive behavioral (CBT-GSH) therapy has been show to be an effective treatment to reduce binge eating for patient with both disorders. (sbir.gov)
  • SGLT2 inhibitors are a new class of oral drugs for the treatment of type 2 diabetes mellitus currently in phase III studies. (bjcardio.co.uk)
  • Treatment with traditional glucose-lowering therapies, including metformin, sulphonylureas and insulin, is commonly limited by gastrointestinal side effects, weight gain and hypoglycaemia. (bjcardio.co.uk)
  • SGLT2 inhibitors represent a novel 'glucuretic' therapeutic strategy for the treatment of type 2 diabetes, and are currently in phase III trials. (bjcardio.co.uk)
  • Conclusions Standardised combination therapy using bevacizumab injections followed by navigated laser treatment for clinically significant diabetic macular oedema demonstrated significant visual gain and CRT reduction after bevacizumab treatment and stabilisation after navigated laser up to 12 months. (bmj.com)
  • Bayer HealthCare AG, Onyx Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Roche announced the initiation of a Phase III trial examining Nexavar® (sorafenib) tablets in combination with Tarceva® (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer. (worldpharmanews.com)
  • This trial will enroll up to 100 patients in two indications (UC and NSCLC) into one of two treatment arms (monotherapy or in combination with KEYTRUDA). (fujifilm.com)
  • The combination treatment (Duaklir, Circassia) is designed to be administered twice-daily via AstraZeneca's breath-actuated inhaler (Pressair). (pharmacytimes.com)
  • A fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide (400 mcg) and long-acting beta-agonist (LABA) formoterol fumarate (12 mcg) has been approved by the FDA for the maintenance treatment of chronic obstructive pulmonary disease (COPD). (pharmacytimes.com)
  • With guidelines recommending combined LAMA and LABA therapy for a number of COPD patient groups, we believe Duaklir® will make an important contribution to the treatment of this debilitating disease," said Michael Asmus, Circassia's Vice President, US Medical Affairs, Circassia. (pharmacytimes.com)
  • In children with acute uncomplicated malaria, response to treatment with ganaplacide/lumefantrine was similar to the rate observed in patients who received artemether-lumefantrine control therapy. (novartis.com)
  • Novartis introduced the first fixed-dose combination ACT in 1999 and has since delivered more than 1 billion courses of antimalarial treatment, largely at no profit. (novartis.com)
  • This is leading to the development of treatment combinations with other therapies to prevent resistance. (outsourcing-pharma.com)
  • The principle of preferentially selecting patients most likely to benefit from therapy according to their genetic profile has led to substantial clinical benefit in some tumour types, and has potential to considerably refine treatment in advanced nonsmall cell lung cancer (NSCLC). (ersjournals.com)
  • Treatment protocols for colon cancer are provided below, including adjuvant and neoadjuvant therapy for resectable disease and therapy for advanced or metastatic colon cancer. (medscape.com)
  • AIMS: The primary aim was to compare the efficacy of smoking cessation treatment using a combination of active nicotine patch plus active nicotine gum versus therapy consisting of active nicotine patch plus placebo gum in a sample of alcohol-dependent tobacco smokers in an early phase of out-patient alcohol treatment. (who.int)
  • Most patients needing surgery for hand dislocation injuries are best served by treatment in the acute phase. (medscape.com)
  • Furthermore, antiangiogenic agents, which have a budding role in the treatment of mesothelioma, may eventually be used by clinicians in combination with immunotherapy, she said. (medscape.com)
  • Notably, three treatment-related deaths were observed in the combination arm (one death from metabolic encephalopathy, one from fulminant hepatitis , and one from acute renal failure ). (medscape.com)
  • Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. (mdpi.com)
  • Various systems biology methods must be used to discover combination therapies to overcome drug resistance in select cancer types. (wikipedia.org)
  • However, with 300 FDA-approved cancer drugs on the market, there almost 45,000 possible two-drug combinations and almost 4.5 million three-drug combinations for to choose from. (wikipedia.org)
  • Background Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. (bmj.com)
  • A clinical trial led by Stephanie L. Goff, M.D. , Associate Research Physician in the Surgery Branch , is researching a therapy for both types of cancer. (cancer.gov)
  • Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. have begun enrolling patients in an international Phase III trial to evaluate Nexavar® (sorafenib) tablets in patients with non-squamous non-small cell lung cancer (NSCLC) who have failed two or three previous treatments. (worldpharmanews.com)
  • The use of Keytruda in combination with chemoradiotherapy provides a valuable tool in treating advanced cervical cancer, an area that has lacked for new therapies in recent years, according to Gursel Aktan, VP of global clinical development at Merck Research Laboratories. (mmm-online.com)
  • The company has collaborated with Moderna on an mRNA cancer vaccine that could treat patients in combination with Keytruda. (mmm-online.com)
  • Therapies tailored to specific genetic lesions and diagnostic tests that assay for their respective molecular targets are now an established part of clinical practice across various tumour types, including chronic myeloid leukaemia 1 , gastrointestinal stromal tumours and epithelial tumours, such as breast and colon cancer 2 . (ersjournals.com)
  • Clinical practice in colon cancer also reflects the need for mutational testing to identify patients most likely to benefit from cetuximab: patients whose tumours lack a KRAS mutation (also called wild-type) show significantly increased overall survival (OS) (median 9.5 versus 4.8 months) with cetuximab, whereas those with KRAS mutations do not benefit from therapy 4 . (ersjournals.com)
  • This review considers the current evidence linking biomarker profile to efficacy of epidermal growth factor receptor (EGFR)-targeted therapy in advanced nonsmall cell lung cancer (NSCLC) and the clinical implications of recent findings. (ersjournals.com)
  • Immunohistochemical examinations of colon tissues showed significantly lower neutrophil counts, more granzyme B-positive but fewer MMP9 (gelatinase B)-positive cancer cells and lower numbers of apoptotic cells in mice receiving AAT therapy. (lu.se)
  • Our results are consistent with previous findings and support an idea that AAT alone and/or in combination with available anti-cancer therapies may represent a new personalized approach for patients with colitis-induced colon cancer. (lu.se)
  • A small phase I clinical trial has tested an anti-HIV strategy involving an adeno-associated viral vector-based gene delivery system that instructs cells to pump out antibodies that block HIV. (sciencedaily.com)
  • The strategy recently generated promising results in a phase I clinical trial that was conducted by the National Institutes of Health and is published in Nature Medicine . (sciencedaily.com)
  • NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("AzurRx" or the "Company"), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has activated two trial sites in Turkey for its Phase 2 Combination Therapy clinical trial to investigate MS1819 in cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI). (firstwavebio.com)
  • We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial," said Dr. James Pennington, Chief Medical Officer of AzurRx. (firstwavebio.com)
  • AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. (firstwavebio.com)
  • Home Pharma Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and. (blstimes.com)
  • In the ARASENS trial, NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) significantly increased overall survival (OS) compared to docetaxel and ADT. (blstimes.com)
  • In addition, new data from the Phase 1b clinical trial sponsored by Janssen Research & Development, LLC (Janssen) evaluating nirogacestat in combination with teclistamab, Janssen's bispecific antibody targeting BCMA and CD3, will be presented in an oral presentation. (advfn.com)
  • We are pleased that updated data from the GSK-sponsored trial continue to support our thesis that the combination with nirogacestat may further optimize the benefit-risk profile of belamaf monotherapy. (advfn.com)
  • The FDA based its decision on the KEYNOTE-A18 trial, which showed Merck's Keytruda in combination with concurrent chemoradiotherapy boosted progression-free survival. (mmm-online.com)
  • The two companies launched a Phase 3 trial for the effort in July. (mmm-online.com)
  • Chari's patient joined the phase 2 STORM trial (NCT02336815), which evaluated the combination of oral selinexor (Xpovio) plus low-dose dexamethasone in patients with refractory heavily pretreated MM. The patient saw significant clinical improvements, including in his renal function, enabling him to join other clinical trials. (onclive.com)
  • For example, Alecensa showed promise ​ in combination with the antibody drug bevacizumab in a phase 2 trial in patients with advanced ALK-positive NSCLC. (outsourcing-pharma.com)
  • Biogen is recruiting for a Phase II trial to confirm BIIB080's safety, tolerability and efficacy in patients with mild and moderate AD. (biospace.com)
  • Searching for Biomarkers to Better Guide Melanoma Therapy Dr Jeffrey Weber explores the phase 3 COMBI-AD melanoma trial. (medscape.com)
  • A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). (bvsalud.org)
  • This randomized phase 2 trial may be enough to support the use of immune checkpoint inhibitors in this setting," Dr Scherpereel said, "but it is too early to conclude whether nivolumab alone or the combination of nivolumab and ipilimumab is better. (medscape.com)
  • Society for Melanoma Research 2022: Adjuvant and TIL Therapy Jeffrey S. Weber, MD, PhD, discusses abstracts presented at the recent Society for Melanoma Research meeting in Edinburgh, Scotland. (medscape.com)
  • Re-treating Melanoma After PD-1 Blockade Shows Good Response In patients who received single-agent PD-1 blockade for melanoma, how effective is second-line therapy? (medscape.com)
  • Jeffrey Weber discusses recent trials investigating neoadjuvant combination immunotherapy in patients with melanoma. (medscape.com)
  • CheckMate 204: 'Practice-Changing' for Metastatic Melanoma The ipilimumab plus nivolumab combination gives patients a reasonable chance of CNS tumor regression, thus not requiring radiation, according to Jeffrey Weber. (medscape.com)
  • 'Optimistic' Longer-term Outcomes for Metastatic Melanoma Targeted therapy and immunotherapy are showing promising longer-term outcomes in metastatic melanoma. (medscape.com)
  • Imeglimin is in development for use both as monotherapy and in combination with other diabetes treatments. (genengnews.com)
  • When injected into a patient, the AAV therapy (called AAV8-VRC07) enters muscle cells, where the genetic sequence is read and translated to produce large quantities of the broadly neutralizing antibody (called VRC07) that are pumped out of the cells and travel through the blood to seek out their target. (sciencedaily.com)
  • In these studies, bNAb resistance emerged in nearly all treated participants who received monotherapy, but in two notable cases 4 the repeated administration of a combination of two bNAbs in the setting of viremia maintained viral suppression for 3 months without development of resistance to either antibody. (nature.com)
  • The Merck Serono spin-out said a large portion of the funds will be used to progress clinical development of its Phase II-stage type 2 diabetes therapy candidate, Imeglimin. (genengnews.com)
  • The firm says figures suggest that there were some 220 million people worldwide with type 2 diabetes in 2007, which resulted in type 2 diabetes therapies achieving a global turnover of some €9.6 billion (about $12 billion). (genengnews.com)
  • 7 The increasing prevalence of type 2 diabetes, in combination with limitations of current therapies, has led to the search for newer alternatives. (bjcardio.co.uk)
  • The investigational antisense oligonucleotide (ASO) therapy reduced biomarkers of tau in cerebrospinal fluid (CSF) across all dose groups. (biospace.com)
  • The use of fixed drug combinations may enhance patient adherence and may reduce the risk of inappropriate monotherapy, and it may prevent the development of secondary drug resistance. (cdc.gov)
  • For this reason, the use of such fixed drug combinations is strongly encouraged in adults. (cdc.gov)
  • AAV vectors can be safely used in humans to deliver DNA to cells, and two AAV-based gene therapies are currently FDA approved. (sciencedaily.com)
  • Could tumor mutational burden alone or in combination with interferon gamma gene signature be a prognostic factor? (medscape.com)
  • Effects of this therapy were evaluated histologically, and by immunohistochemical and gene expression assays. (lu.se)
  • One major benefit of combination therapies is that they reduce development of drug resistance since a pathogen or tumor is less likely to have resistance to multiple drugs simultaneously. (wikipedia.org)
  • Existing pharmacological therapies, which have been previously described in this series, are focused on reducing insulin resistance, increasing insulin secretion, slowing carbohydrate digestion, restraining glucagon production, and supplying exogenous insulin. (bjcardio.co.uk)
  • A 4-mo regimen of isoniazid and rifampin is acceptable therapy for adults who have active tuberculosis and who are sputum-smear and culture negative, if there is little possibility of drug resistance (see Section 1 above). (cdc.gov)
  • The model uses a combination of Machine Learning (ML) and a GlobalData proprietary algorithm to process data points from the Drugs, Clinical Trials, Regulatory Milestones, Company, and Financial databases. (globaldata.com)
  • In 2018, he discussed hospice with a patient with advanced MM refractory to all available therapies and chronic kidney dysfunction that made it difficult to enroll him in nearly all clinical trials. (onclive.com)
  • The aclidinium bromide/formoterol fumarate therapy is on track to launch in the United States in the second half of 2019, according to Circassia. (pharmacytimes.com)
  • When the FDA approved selinexor for patients with MM in 2019, 4 the patient was able to receive the therapy again in combination with other MM agents. (onclive.com)
  • Some preliminary results show that increasing the duration of therapy to 6 or 8 months further reduces tumor volume and PSA nadir levels and decreases the likelihood of positive margins. (medscape.com)
  • The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). (bvsalud.org)
  • That level of complexity is one of the primary impediments to the growth of combination therapy in oncology. (wikipedia.org)
  • T has recently highlighted combination therapy as a top research priority in oncology. (wikipedia.org)
  • Plus, it appears that immunotherapy may offer something not seen previously in second-line therapy: improved overall survival. (medscape.com)
  • More data are needed to determine the utility of combination immunotherapy vs nivolumab alone, said Dr Scherpereel. (medscape.com)
  • Darolutamide reduced the risk of death by 32% despite a high rate of subsequent life-prolonging systemic therapy in the placebo group. (urotoday.com)
  • Meanwhile, recent basic and clinical evidence have revealed another aspect of KIT-targeted therapy, namely the enhancement of antitumor activity of immune checkpoint inhibitors. (elsevierpure.com)
  • Preclinical studies have demonstrated that the combination* 5 of FF-10832 and immune checkpoint inhibitors impact CD8-positive T cells* 6 and may lead to longer survival compared to monotherapy* 7 . (fujifilm.com)
  • Merck Serono spin-out progressing oral therapy for type 2 disease through Phase II trials. (genengnews.com)
  • These positive results support the future progression of the combination in patients with acute uncomplicated malaria. (novartis.com)
  • Conclusion: Human AAT is an acute phase protein with a broad-protease inhibitory and immunomodulatory activities used as a therapeutic for emphysema patients with inherited AAT deficiency. (lu.se)
  • Fujifilm has completed the phase 1 dose escalation of FF-10832 monotherapy, and is currently conducting an expansion phase. (fujifilm.com)
  • This combination has the potential not only to clear malaria infection, including artemisinin resistant strains, but also to block the transmission of the malaria parasite. (novartis.com)
  • With this phase 2b data we remain cautiously optimistic that ganaplacide/lumefantrine could one day be saving the lives of those at greatest risk of malaria - young children. (novartis.com)
  • Plasmodium falciparum malaria is primarily treated with artemisinin combination therapies (ACTs) such as artemether-lumefantrine. (novartis.com)
  • Aim To evaluate the efficacy of a standardised combination therapy for clinically significant diabetic macular oedema using bevacizumab injections followed by navigated laser photocoagulation to stabilise retinal thickness. (bmj.com)
  • The evidence to date suggests that adherence to therapy and clinical outcomes in developing world programmes are at least the equal of those observed in developed countries. (lww.com)
  • A secondary aim was to determine whether or not there were any carry-over effects of combination nicotine replacement on drinking outcomes. (who.int)
  • The Food and Drug Administration granted Merck a priority review for its application for Keytruda in combination with concurrent chemoradiotherapy, the company announced Wednesday. (mmm-online.com)
  • ARASENS was designed to evaluate the effect of darolutamide in combination with ADT and docetaxel on OS in patients with mHSPC. (urotoday.com)
  • Key secondary endpoints, including time to mCRPC, time to pain progression, time to symptomatic skeletal event (SSE), and time to subsequent anti-neoplastic therapy, all favored the addition of darolutamide to ADT plus docetaxel. (urotoday.com)
  • Dr. Smith concluded that darolutamide in combination with ADT and docetaxel significantly improved OS compared with ADT and docetaxel in patients with mHSPC. (urotoday.com)
  • Countries and districts are stratified into four phases based on the parasite prevalence or the Annual Parasite Index (API). (who.int)
  • In phase 1, programmes are in control mode and are characterized by more than 5% parasite prevalence or API of five or more per 1000 population. (who.int)
  • Phase 2 encompasses pre-elimination programmes and is characterized by parasite prevalence of less than 5% in all ages, or API of 2 - 4 per 1000 population, with focalized and seasonal transmission. (who.int)
  • Secondary objective is to improve circulating hyperandrogenemia and insulin sensitivity then single agent therapy. (knowcancer.com)
  • Secondary objective is to improve ovulatory frequency and insulin sensitivity than just the use of a single agent therapy. (knowcancer.com)
  • A recent re-evaluation of this regimen in Africa with multiple doses of intrathecal therapy compares favourably with recent studies of single agent CTX, and other drugs have been shown to be non-cross resistant. (hindawi.com)
  • The combination of ganaplacide/lumefantrine solid dispersion formulation was generally well tolerated in the children. (novartis.com)
  • Typically, the term refers to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and talk therapy to treat depression). (wikipedia.org)
  • Optimal results for patients with extensive disease probably require 5 or 6 effective drugs along with intrathecal therapy, using MTX and Ara-C. In Africa, doses must be lower, because of limitations in supportive care, but in technically advanced countries cure rates in excess of 90% can be obtained. (hindawi.com)
  • About 10% of the total population of SCLC patients remains free of disease during the 2 years from the start of therapy, which is the time period during which most relapses occur. (cancer.gov)
  • After his disease went into remission again, this patient has now received 2 different T-cell-redirection therapies when those remissions ended. (onclive.com)
  • Although access to first-line therapy is reasonably well established, there is a substantial and unacceptable mortality rate in the first 6 months after initiation of ART, particularly in those with low CD4 cell counts and late-stage disease. (lww.com)
  • With approvals for Aduhelm (aducanumab) and Leqembi (lecanemab) under its belt, Biogen presented data Wednesday for an Alzheimer's disease therapy with a different target at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2023) in Stockholm, Sweden. (biospace.com)